The Cell & Gene Meeting on the Mediterranean, produced by the Alliance for Regenerative Medicine (ARM), is a two-day conference for the cell and gene therapy community from Europe and beyond. The conference will cover a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector. The program will also feature expert-led panels, extensive 1×1 partnering, networking, and 40+ presentations by the leading publicly traded and privately held companies in the space.

Meeting on the Med in Numbers:

• 500+ 1×1 partnering meetings
• 250+ company executives, investors, patient advocates and large pharma representatives in attendance
• 50+ industry experts discussing topics ranging from market access to the latest discoveries in T-cell therapies
• 40+ presentations by the field’s most prominent publicly traded and emerging private companies
• 5+ interactive panel sessions addressing critical commercial, scientific, regulatory and market access issues